GlycoMimetics to Present at Upcoming H.C. Wainwright & Co Annual Global Investment Virtual Conference
September 08 2020 - 04:00PM
Business Wire
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief
Executive Officer Rachel King will present at the upcoming H.C.
Wainwright & Co 22nd Annual Global Investment Virtual
Conference taking place September 14-16, 2020. The presentation
will be available on the company’s website at the “Investors” tab
for 30 days, beginning Monday, September 14 at 2:30 p.m. EDT.
To access the live webcast and subsequent archived recordings
for the presentation, please visit the GlycoMimetics website at
https://ir.glycomimetics.com/investor-relations
About GlycoMimetics, Inc.
GlycoMimetics is a biotechnology company with two late-stage
clinical development programs and a pipeline of novel glycomimetic
drugs, all designed to address unmet medical needs resulting from
diseases in which carbohydrate biology plays a key role.
GlycoMimetics' drug candidate, uproleselan, an E-selectin
antagonist, was evaluated in a Phase 1/2 clinical trial as a
potential treatment for AML and is being evaluated across a range
of patient populations including a Company-sponsored Phase 3 trial
in relapsed/refractory AML under breakthrough therapy designation.
Rivipansel, a pan-selectin antagonist, is being explored as a
potential treatment for acute vaso-occlusive crisis in sickle cell
disease. GlycoMimetics has also completed a Phase 1 clinical trial
with another wholly-owned drug candidate, GMI-1359, a combined
CXCR4 and E-selectin antagonist. GlycoMimetics is located in
Rockville, MD in the BioHealth Capital Region. Learn more at
www.glycomimetics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200908005907/en/
GlycoMimetics Contacts
Investor Contact:
Shari Annes Phone: 650-888-0902 Email:
sannes@annesassociates.com
Media Contact:
Jamie Lacey-Moreira Phone: 410-299-3310 Email:
jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Feb 2024 to Mar 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Mar 2023 to Mar 2024